Market Trends– category –
-
Advancements in Cell and Gene Therapy Manufacturing: Automation, Cost Reduction, and Scalability Revolutionize Patient Access
Bioprocessing Summit Europe International Overview The cell and gene therapy (CGT) manufacturing sector faces significant operational challenges, including high costs and scalability constraints, particularly due to raw material variabil... -
Capra Biosciences Boosts Domestic Manufacturing of Essential Medicines with Continued HHS Support, Strengthening Biopharmaceutical Supply Chain Resilience
BioSpace USA Overview Capra Biosciences announced plans to strengthen its domestic manufacturing capabilities for essential medicines with ongoing financial support from the U.S. Department of Health and Human Services (HHS). This initia... -
Fate Therapeutics’ iPSC-Derived CAR-T FT819 Shows Safety and Improved Skin Scores in Refractory Systemic Sclerosis Phase 1; Repligen Acquires BioLife Solutions for $1.5 Billion
DeciBio USA Overview July 2026 highlights in next-generation therapeutics include Fate Therapeutics' preliminary Phase 1 data for FT819, an iPSC-derived CD19-targeted CAR-T cell therapy for treatment-refractory systemic sclerosis, demons... -
Vertex’s CASGEVY Gene Therapy Expands FDA Approval to Pediatric Patients 2+ for Sickle Cell and Beta-Thalassemia; Umoja’s In Vivo CAR-T for Solid Tumors Enters Clinic
BioInsights USA Overview July 2026 marked significant progress in gene and cell therapy access, with Vertex Pharmaceuticals' CASGEVY receiving expanded FDA approval for pediatric patients aged 2 and older with sickle cell disease and tra... -
FDA Issues Warnings as No Approved Therapeutic Exosomes Exist in 2026 Amidst Reports of Adverse Events
OmniGenix USA Overview As of 2026, the U.S. FDA has not approved any therapeutic exosome products, issuing warnings against unauthorized sales due to reported adverse events. A 2025 review of clinical trials from 2014-2024 indicated favo... -
BlossomHill and Latigo Secure $496 Million in Combined IPOs, Fueling Clinical-Stage Cancer and Non-Opioid Pain Therapies
Endpoints News USA Overview BlossomHill Therapeutics and Latigo Biotherapeutics successfully completed their IPOs, raising a combined total of $496 million, with $150 million for BlossomHill and $346 million for Latigo. These substantial... -
Private Investors Reroute $8.8 Billion into Emerging Market AI Data Centers, Reshaping Global AI Infrastructure Strategy
Briefs Finance USA Overview In the first half of 2026, private investors poured a significant $8.8 billion into AI projects in developing nations, primarily funding data centers and AI companies. Regions like India, China, Mexico, Africa... -
KKR Acquires Medtech Giant Integer Holdings for $5.7 Billion, Signaling AI’s Growing Influence on Biotech Investment
Fierce Biotech USA Overview KKR has sealed a $5.7 billion deal to take Integer Holdings, a prominent medical technology manufacturer, private. This significant M&A transaction underscores a broader trend of large-scale deals within t... -
GlobalFoundries Secures $300M in $874M CHIPS Act Push for AI-Photonics Integration
Benzinga USA Overview The U.S. Department of Commerce has announced $874 million in federal incentives under the CHIPS and Science Act, distributed among seven companies, to advance semiconductor technologies for AI and high-performance ... -
Goldman Sachs: AI Infrastructure Investment Soars Beyond Hyperscalers, MediaTek and Qualcomm Eye Billions in AI Datacenter Revenue
ET Datacenters News (citing Goldman Sachs) USA Overview A Goldman Sachs research report reveals a significant surge in AI infrastructure investment during July, driven by expanding enterprise adoption and sovereign AI initiatives beyond ...
